GHK-Cu amino acid sequence and studies
GHK-Cu is a copper-binding peptide used in skincare. Small topical studies and laboratory findings need to be kept separate from injection claims.
Topical studies concern the skin surface and the preparation tested; they do not establish injection benefits.
GHK and copper
GHK consists of three amino acids: glycine, histidine and lysine. GHK-Cu is the copper-bound form. Copper tripeptide-1 is a common cosmetic ingredient name for it. Free GHK, the copper complex and chemically modified relatives are not interchangeable study materials.
A review of skin-regeneration biology describes effects on fibroblasts, the cells that make much of the skin’s supporting material. Collagen is one of those structural proteins. Cell-culture findings explain the interest in GHK-Cu, but do not demonstrate a visible result from a cream or an injection.
What topical studies measured
The human topical record is small. Reviews describe changes in skin appearance and collagen-related measures, but the underlying studies vary in design and accessibility. A 2025 review of topical GHK identifies a shortage of clinical studies alongside interest in the laboratory findings.
The 2015 review reports a pilot in which a proportion of women showed increased collagen after topical treatment. That is a proportion of participants with a response, not a percentage increase in the amount of collagen. It also does not establish a whole-body effect or a result from an injected preparation.
Skin outcomes are specific. A change in a sample of tissue, an assessor’s wrinkle score and a person’s satisfaction are different measures. A useful summary names the measure instead of combining them into a general claim of rejuvenation.
The hair trial used combined ingredients
A 2016 hair study in forty-five men compared a topical combination of free GHK and 5-aminolevulinic acid with placebo over six months. Hair counts rose more in the active groups. Hair thickness did not change, and no adverse events were reported.
This was not a trial of GHK-Cu alone. The formulation contained another active ingredient, and the peptide was not the copper complex. The trial cannot separate each ingredient’s contribution. Its result belongs to that combination in that group of participants, rather than to every product described as a copper peptide.
Getting through the skin barrier
Skin is an effective barrier. An ingredient that changes cells in a dish still has to reach the relevant tissue when applied to intact skin. The 2025 topical review treats delivery as a central formulation problem.
A study using human skin outside the body measured copper penetration and retention after GHK-Cu exposure. It found copper in skin layers under experimental conditions. The measurement was of copper, not proof that an intact peptide reached a target in a living person or produced a cosmetic benefit.
Changing the formulation also changes the question being tested. Evidence for one preparation cannot automatically support another route, concentration or delivery method. This is particularly important when topical findings are used to discuss systemic exposure.
Safety depends on the route
Small topical studies have not supplied a large safety record. Their reassuring observations cannot exclude uncommon reactions or settle longer use. Community descriptions of redness, itching, dryness or changes in skin appearance are anecdotal, not clinical evidence.
For injections, FDA identifies potential immune reactions, including concerns linked to clumping and impurities. It also notes limited human data. This is a risk assessment, not a documented rate of harm. Validated human pharmacokinetic data for injected GHK-Cu remain lacking.
There is no FDA-approved GHK-Cu drug label with an established dosing schedule, interaction list or pregnancy guidance. Cosmetic use at the skin surface does not answer those questions for an injected preparation.
Cosmetic use and drug status
GHK-Cu has no FDA-approved drug product. Its use as a cosmetic ingredient is a different regulatory context. Cosmetic status does not mean FDA has approved it as a treatment, and it does not support an injection claim.
On FDA’s page current as of April 22, 2026, GHK-Cu for injectable routes is listed as nominated but withdrawn. Withdrawal is not clearance or approval for compounding. The route qualification matters: the injectable entry must not be used as a summary of every non-injected form.
The comparison keeps these routes beside the very different BPC-157 and TB-500 records. The references distinguish the skin reviews, the combination hair trial and FDA’s assessment.